Alkermes plc Reports Third Quarter 2021 Financial Results
Alkermes plc (Nasdaq: ALKS) reported third-quarter 2021 revenues of $294.1 million, up from $265.0 million the previous year, with net sales of proprietary products reaching $157.7 million. The launch of LYBALVI expanded their psychiatry franchise. However, total operating expenses rose to $313.8 million, resulting in a GAAP net loss of $29.0 million. Despite the loss, non-GAAP net income was $23.6 million. Alkermes maintains its 2021 financial guidance, contingent on improving patient access and treatment normalization.
- Total revenue grew by 11% year-over-year to $294.1 million.
- Net sales of proprietary products increased to $157.7 million, with VIVITROL sales up 11% to $88.8 million.
- Successful launch of LYBALVI, enhancing the company's psychiatry portfolio.
- Initiated significant clinical studies for nemvaleukin in oncology, including phase 3 trials.
- Total operating expenses increased to $313.8 million, up from $275.7 million.
- GAAP net loss of $29.0 million, worsening from a near breakeven last year.
DUBLIN, Oct. 27, 2021 /PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the third quarter of 2021.
"We have made significant strides across our commercial and development portfolios over the course of 2021. With the recent commercial launch of LYBALVI®, we have expanded our psychiatry franchise and added an important new growth opportunity that leverages our experience and capabilities in the antipsychotic market. Within our development pipeline, we initiated clinical studies designed to support potential registration of nemvaleukin in mucosal melanoma and platinum-resistant ovarian cancer. We also initiated a phase 1 study of ALKS 1140 and advanced our preclinical orexin 2 receptor agonist program. Each of these important achievements demonstrates the continued execution of our strategy to advance differentiated medicines in neuroscience and oncology," said Richard Pops, Chief Executive Officer of Alkermes. "As we look ahead, we believe we are well-positioned to deliver long-term growth and value creation, driven by our diversified commercial business, our advancing development pipeline and our focus on profitability."
Quarter Ended Sept. 30, 2021 Financial Results
Revenues
- Total revenues for the quarter were
- Net sales of proprietary products for the quarter were
- Net sales of VIVITROL® were
$88.8 million , compared to$80.3 million for the same period in the prior year, representing an increase of approximately11% . - Net sales of ARISTADA®i were
$68.9 million , compared to$62.4 million for the same period in the prior year, representing an increase of approximately10% .
- Manufacturing and royalty revenues for the quarter were
- Manufacturing and royalty revenues from INVEGA SUSTENNA®/XEPLION®, INVEGA TRINZA®/TREVICTA®, and RISPERDAL CONSTA® were
$90.3 million , compared to$87.9 million for the same period in the prior year. - Manufacturing and royalty revenues from VUMERITY® were
$26.7 million , compared to$2.7 million for the same period in the prior year.
Costs and Expenses
- Total operating expenses for the quarter were
- Cost of Goods Manufactured and Sold were
$49.6 million , compared to$43.1 million for the same period in the prior year. - Research and Development (R&D) expenses were
$118.4 million , compared to$95.0 million for the same period in the prior year. R&D expenses for the third quarter included accrual of a$25.0 million development milestone to be paid to the former shareholders of Rodin Therapeutics, Inc. related to ALKS 1140, the first clinical candidate to emerge from the histone deacetylase (HDAC) inhibitor platform acquired by Alkermes in 2019. Excluding this milestone, R&D expenses for the quarter were$93.4 million . - Selling, General and Administrative (SG&A) expenses were
$136.2 million , compared to$127.7 million for the same period in the prior year, primarily reflecting increased investment to support the launch of LYBALVI.
Profitability
- Net loss according to generally accepted accounting principles in the U.S. (GAAP) was
- Non-GAAP net income was
Balance Sheet
- At Sept. 30, 2021, the company recorded cash, cash equivalents and total investments of
Financial Expectations for 2021
Alkermes reiterates its financial expectations for 2021 set forth in its press release dated July 28, 2021. These financial expectations assume improvement in patient access to treatment providers and further normalization of the treatment system in the fourth quarter of 2021. If patient access does not improve or the treatment system does not normalize as anticipated, or if new COVID-19-related disruptions emerge, the company's ability to meet these expectations could be negatively impacted.
"We are pleased to report another strong quarter that reflects our continued focus on commercial execution, with solid year-over-year growth for VIVITROL and ARISTADA, and on driving operational efficiencies," commented Iain Brown, Chief Financial Officer of Alkermes. "As we look ahead, we believe that we are in a strong financial position to successfully launch LYBALVI and invest in our pipeline of development candidates as we seek to drive long-term value creation and profitability."
Recent Events:
Psychiatry
- In October 2021, the company announced the commercial availability of LYBALVI (olanzapine and samidorphan) in the U.S. for the treatment of adults with schizophrenia, and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes as monotherapy or an adjunct to lithium or valproateii. LYBALVI is a once-daily, oral atypical antipsychotic composed of olanzapine, an established antipsychotic agent, co-formulated with samidorphan, a new chemical entity, in a single bilayer tablet.
Oncology
- In August 2021, the U.S. Food and Drug Administration (FDA) granted Fast Track designation to nemvaleukin alfa (nemvaleukin) for the treatment of mucosal melanoma. This followed the FDA's grant of Orphan Drug designation to nemvaleukin for the treatment of mucosal melanoma and the recent initiation of ARTISTRY-6, a global phase 2 trial evaluating the anti-tumor activity, safety and tolerability of nemvaleukin monotherapy in patients with melanoma who have been previously treated with anti-PD-(L)1 therapy.
- In October 2021, the FDA granted Fast Track designation to nemvaleukin in combination with pembrolizumab for the treatment of platinum-resistant ovarian cancer.
- In October 2021, the company announced the initiation of ARTISTRY-7, a global phase 3 trial evaluating the anti-tumor activity and safety of intravenously administered (IV) nemvaleukin in combination with pembrolizumab compared to investigator's choice chemotherapy in patients with platinum-resistant ovarian cancer.
Neuroscience
- In October 2021, the company initiated a phase 1, first-in-human study evaluating the safety and tolerability of ALKS 1140 in healthy subjects. ALKS 1140 is a novel, investigational CoREST-selective (co-repressor of repressor element-1 silencing transcription factor) HDAC inhibitor candidate for the treatment of neurodegenerative and neurodevelopmental disorders. ALKS 1140 is designed to increase functional synaptic connections and synaptic integrity in the brain.
Conference Call
Alkermes will host a conference call and webcast presentation with accompanying slides at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, Oct. 27, 2021, to discuss these financial results and provide an update on the company. The webcast may be accessed on the Investors section of Alkermes' website at www.alkermes.com. The conference call may be accessed by dialing +1 877 407 2988 for U.S. callers and +1 201 389 0923 for international callers. In addition, a replay of the conference call may be accessed by visiting Alkermes' website.
About Alkermes plc
Alkermes plc is a fully-integrated, global biopharmaceutical company developing innovative medicines in the fields of neuroscience and oncology. The company has a portfolio of proprietary commercial products focused on addiction, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurodegenerative disorders and cancer. Headquartered in Dublin, Ireland, Alkermes has an R&D center in Waltham, Massachusetts; a research and manufacturing facility in Athlone, Ireland; and a manufacturing facility in Wilmington, Ohio. For more information, please visit Alkermes' website at www.alkermes.com.
Non-GAAP Financial Measures
This press release includes information about certain financial measures that are not prepared in accordance with GAAP, including non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share. These non-GAAP measures are not based on any standardized methodology prescribed by GAAP and are not necessarily comparable to similar measures presented by other companies.
Non-GAAP net income (loss) adjusts for certain one-time and non-cash charges by excluding from GAAP results: share-based compensation expense; amortization; depreciation; non-cash net interest expense; certain other one-time or non-cash items; and the income tax effect of these reconciling items.
The company's management and board of directors utilize these non-GAAP financial measures to evaluate the company's performance. The company provides these non-GAAP measures of the company's performance to investors because management believes that these non-GAAP financial measures, when viewed with the company's results under GAAP and the accompanying reconciliations, are useful in identifying underlying trends in ongoing operations. However, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share are not measures of financial performance under GAAP and, accordingly, should not be considered as alternatives to GAAP measures as indicators of operating performance. Further, non-GAAP net income (loss) and non-GAAP basic and diluted earnings (loss) per share should not be considered measures of the company's liquidity.
A reconciliation of GAAP to non-GAAP financial measures has been provided in the tables included in this press release.
Note Regarding Forward-Looking Statements
Certain statements set forth in this press release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, but not limited to, statements concerning: the company's expectations concerning its future financial and operating performance, business plans or prospects, including its ability to deliver, and the expected drivers of, growth and value creation; the company's expectations of improvement in patient access to treatment providers and further normalization of the treatment system; the potential therapeutic and commercial value of the company's marketed and development products; the company's expectations concerning its future development activities, including further investment in and advancement of the company's neuroscience and oncology development pipeline; and the company's expectations concerning its commercial activities, including its ability to successfully launch LYBALVI and to leverage its commercial experience and capabilities in the antipsychotic market. The company cautions that forward-looking statements are inherently uncertain. The forward-looking statements are neither promises nor guarantees and they are necessarily subject to a high degree of uncertainty and risk. Actual performance and results may differ materially from those expressed or implied in the forward-looking statements due to various risks and uncertainties. These risks and uncertainties include, among others: the company may not be able to achieve its targeted financial and profitability metrics in a timely manner or at all; unexpected costs or delays in the commercial launch of LYBALVI; whether LYBALVI will be commercialized successfully; whether third-party payers will cover or reimburse LYBALVI for the treatment of adults with schizophrenia or the treatment of adults with bipolar I disorder; the impacts of the ongoing COVID-19 pandemic and continued efforts to mitigate its spread on the company's business, results of operations or financial condition, including impacts on healthcare systems and patient and healthcare provider access to the company's commercial products and impacts on the regulatory agencies with which the company interacts in the development, review, approval and commercialization of its medicines; the unfavorable outcome of litigation, including so-called "Paragraph IV" litigation and other patent litigation, or other disputes related to the company's products or products using the company's proprietary technologies; clinical development activities may not be completed on time or at all; the results of the company's development activities may not be positive, or predictive of final results from such activities, results of future development activities or real-world results; data from clinical trials may be interpreted by the FDA in different ways than the company interprets it; the FDA may not agree with the company's regulatory approval strategies or components of its filings, including its clinical trial designs, conduct and methodologies and the adequacy of the data and other information included in its submissions to support the FDA's requirements for approval; regulatory submissions may not occur or be submitted in a timely manner; the FDA or regulatory authorities outside the U.S. may make adverse decisions regarding the company's products; the company and its licensees may not be able to continue to successfully commercialize their products; there may be a reduction in payment rate or reimbursement for the company's products or an increase in the company's financial obligations to government payers; the company's products may prove difficult to manufacture, be precluded from commercialization by the proprietary rights of third parties, or have unintended side effects, adverse reactions or incidents of misuse; and those risks and uncertainties described under the heading "Risk Factors" in the company's Annual Report on Form 10-K for the year ended Dec. 31, 2020 and in subsequent filings made by the company with the U.S. Securities and Exchange Commission (SEC), which are available on the SEC's website at www.sec.gov. Existing and prospective investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, the company disclaims any intention or responsibility for updating or revising any forward-looking statements contained in this press release.
VIVITROL® is a registered trademark of Alkermes, Inc.; ARISTADA®, ARISTADA INITIO® and LYBALVI® are registered trademarks of Alkermes Pharma Ireland Limited; RISPERDAL CONSTA®, INVEGA SUSTENNA®, XEPLION®, INVEGA TRINZA® and TREVICTA® are registered trademarks of Johnson & Johnson Company; and VUMERITY® is a registered trademark of Biogen MA Inc., used by Alkermes under license.
(tables follow)
Alkermes plc and Subsidiaries | ||||
Selected Financial Information (Unaudited) | ||||
Condensed Consolidated Statements of Operations - GAAP | Three Months Ended | Three Months Ended | ||
(In thousands, except per share data) | September 30, 2021 | September 30, 2020 | ||
Revenues: | ||||
Product sales, net | $ 157,737 | $ 142,658 | ||
Manufacturing and royalty revenues | 136,294 | 120,351 | ||
Research and development revenue | 110 | 953 | ||
License revenue | — | 1,050 | ||
Total Revenues | 294,141 | 265,012 | ||
Expenses: | ||||
Cost of goods manufactured and sold | 49,561 | 43,129 | ||
Research and development | 118,411 | 94,980 | ||
Selling, general and administrative | 136,213 | 127,653 | ||
Amortization of acquired intangible assets | 9,615 | 9,917 | ||
Total Expenses | 313,800 | 275,679 | ||
Operating Loss | (19,659) | (10,667) | ||
Other (Expense) Income, net: | ||||
Interest income | 468 | 1,376 | ||
Interest expense | (2,437) | (1,811) | ||
Change in the fair value of contingent consideration | (5,195) | 3,926 | ||
Other income, net | 288 | 9,368 | ||
Total Other (Expense) Income, net | (6,876) | 12,859 | ||
(Loss) Income Before Income Taxes | (26,535) | 2,192 | ||
Provision for Income Taxes | 2,453 | 2,326 | ||
Net Loss — GAAP | $ (28,988) | $ (134) | ||
(Loss) Earnings Per Share: | ||||
GAAP loss per share — basic and diluted | $ (0.18) | $ (0.00) | ||
Non-GAAP earnings per share — basic | $ 0.15 | $ 0.26 | ||
Non-GAAP earnings per share — diluted | $ 0.14 | $ 0.26 | ||
Weighted Average Number of Ordinary Shares Outstanding: | ||||
Basic and diluted — GAAP | 161,456 | 159,062 | ||
Basic — Non-GAAP | 161,456 | 159,062 | ||
Diluted — Non-GAAP | 166,758 | 160,335 | ||
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows: | ||||
Net Loss — GAAP | $ (28,988) | $ (134) | ||
Adjustments: | ||||
Share-based compensation expense | 25,600 | 22,618 | ||
Depreciation expense | 9,775 | 10,663 | ||
Amortization expense | 9,615 | 9,917 | ||
Income tax effect related to reconciling items | 2,243 | 2,174 | ||
Non-cash net interest expense | 117 | 166 | ||
Change in the fair value of contingent consideration | 5,195 | (3,926) | ||
Non-GAAP Net Income | $ 23,557 | $ 41,478 | ||
Condensed Consolidated Statements of Operations - GAAP | Nine Months Ended | Nine Months Ended | ||
(In thousands, except per share data) | September 30, 2021 | September 30, 2020 | ||
Revenues: | ||||
Product sales, net | $ 448,508 | $ 402,799 | ||
Manufacturing and royalty revenues | 398,435 | 353,107 | ||
License revenue | 1,500 | 1,050 | ||
Research and development revenue | 845 | 1,805 | ||
Total Revenues | 849,288 | 758,761 | ||
Expenses: | ||||
Cost of goods manufactured and sold | 143,705 | 135,394 | ||
Research and development | 308,152 | 282,481 | ||
Selling, general and administrative | 400,569 | 393,049 | ||
Amortization of acquired intangible assets | 28,532 | 29,535 | ||
Total Expenses | 880,958 | 840,459 | ||
Operating Loss | (31,670) | (81,698) | ||
Other (Expense) Income, net: | ||||
Interest income | 1,955 | 5,924 | ||
Interest expense | (8,814) | (6,790) | ||
Change in the fair value of contingent consideration | (677) | 16,626 | ||
Other (expense) income, net | (327) | 11,047 | ||
Total Other (Expense) Income, net | (7,863) | 26,807 | ||
Loss Before Income Taxes | (39,533) | (54,891) | ||
Provision for Income Taxes | 9,509 | 13,328 | ||
Net Loss — GAAP | $ (49,042) | $ (68,219) | ||
(Loss) Earnings Per Share: | ||||
GAAP loss per share — basic and diluted | $ (0.31) | $ (0.43) | ||
Non-GAAP earnings per share — basic | $ 0.56 | $ 0.33 | ||
Non-GAAP earnings per share — diluted | $ 0.55 | $ 0.33 | ||
Weighted Average Number of Ordinary Shares Outstanding: | ||||
Basic and diluted — GAAP | 160,642 | 158,685 | ||
Basic — Non-GAAP | 160,642 | 158,685 | ||
Diluted — Non-GAAP | 164,077 | 159,467 | ||
An itemized reconciliation between net loss on a GAAP basis and non-GAAP net income is as follows: | ||||
Net Loss — GAAP | $ (49,042) | $ (68,219) | ||
Adjustments: | ||||
Share-based compensation expense | 68,603 | 65,277 | ||
Depreciation expense | 28,978 | 31,991 | ||
Amortization expense | 28,532 | 29,535 | ||
Income tax effect related to reconciling items | 10,349 | 8,971 | ||
Non-cash net interest expense | 352 | 500 | ||
Debt refinancing charge | 2,109 | — | ||
Change in the fair value of contingent consideration | 677 | (16,626) | ||
Acquisition of IPR&D | — | 674 | ||
Non-GAAP Net Income | $ 90,558 | $ 52,103 | ||
Condensed Consolidated Balance Sheets | September 30, | December 31, | ||
(In thousands) | 2021 | 2020 | ||
Cash, cash equivalents and total investments | $ 748,155 | $ 659,807 | ||
Receivables | 289,160 | 275,143 | ||
Inventory | 138,696 | 125,738 | ||
Contract assets | 3,509 | 14,401 | ||
Prepaid expenses and other current assets | 61,341 | 60,662 | ||
Property, plant and equipment, net | 340,594 | 350,003 | ||
Intangible assets, net and goodwill | 176,532 | 204,064 | ||
Other assets | 237,445 | 259,912 | ||
Total Assets | $ 1,995,432 | $ 1,949,730 | ||
Long-term debt — current portion | $ 3,000 | $ 2,843 | ||
Other current liabilities | 449,984 | 435,415 | ||
Long-term debt | 293,437 | 272,118 | ||
Contract liabilities — long-term | 12,864 | 16,397 | ||
Other long-term liabilities | 139,979 | 155,975 | ||
Total shareholders' equity | 1,096,168 | 1,066,982 | ||
Total Liabilities and Shareholders' Equity | $ 1,995,432 | $ 1,949,730 | ||
Ordinary shares outstanding (in thousands) | 161,686 | 159,161 | ||
This selected financial information should be read in conjunction with the consolidated financial statements and notes thereto included in Alkermes plc's Quarterly Report on Form 10-Q for the three and nine months ended September 30, 2021, which the company intends to file in October 2021. |
i The term "ARISTADA" as used in this press release refers to ARISTADA and ARISTADA INITIO®, unless the context indicates otherwise.
ii Full prescribing information, including boxed warning, for LYBALVI may be found at www.lybalvi.com/lybalvi-prescribing-information.pdf
Alkermes Contacts: | ||
For Investors: | Sandy Coombs | +1 781 609 6377 |
For Media: | Katie Joyce | +1 781 249 8927 |
View original content to download multimedia:https://www.prnewswire.com/news-releases/alkermes-plc-reports-third-quarter-2021-financial-results-301409307.html
SOURCE Alkermes plc
FAQ
What were Alkermes' Q3 2021 financial results?
How did the launch of LYBALVI impact Alkermes' financials?
What is Alkermes' financial outlook for the rest of 2021?
What are the key clinical developments announced by Alkermes?
How did Alkermes' expenses change in Q3 2021?
